Chemo, radiation, and immunotherapy for rectal squamous cell carcinoma
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy (cisplatin and 5-FU), radiation, and an immunotherapy drug (PD-1 antibody) for people with a rare type of rectal cancer that hasn't spread. The goal is to see if this treatment can shrink or eliminate the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific type of rectal cancer called squamous cell carcinoma that has not spread to other parts of the body.
- You should not have had any previous treatment for this cancer, like surgery, chemotherapy, or radiation.
- You must be between 18 and 75 years old and in generally good health, with certain blood counts and liver/kidney function within normal limits.
- You should not have had another cancer in the past or serious heart or blood clot problems recently.
- You must be able to take part in the study and follow the instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This study tests a combination of radiation, chemotherapy, and an immunotherapy drug (toripalimab) before surgery for patients whose rectal cancer has returned locally. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
Hear when a new Rectal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.